Matthew Hogan | IR |
James Brown | Co-Founder, CEO, President & Director |
Norman Sussman | Chief Medical Officer |
François Brisebois | Oppenheimer |
Thomas Yip | HC Wainwright |
Geoffrey de Sibert | KB Advisors |
Good afternoon, and welcome to our First Quarter 2022 Earnings Conference Call. This is Matt Hogan, from DURECT Corporation.
Before beginning, I'd like to remind you of our safe harbor statement.
During the course of this call, we may make forward-looking statements regarding DURECT's products and development, expected product benefits, our development plans, future clinical trials or projected financial results. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements.